RedHill Biopharma Acquires Ferring's GI Drugs for $12M, Bolsters Commercial Portfolio
Event summary
- RedHill Biopharma acquired exclusive commercialization rights to Ferring's Rebyota and Clenpiq for a $12M upfront payment.
- Rebyota and Clenpiq generated $37.5M in combined U.S. net sales in 2025.
- The acquisition follows RedHill's $18M divestiture of Talicia, using proceeds to fund the new deal.
- RedHill gains global rights to Rebyota and U.S. rights to Clenpiq, with Ferring retaining manufacturing responsibilities.
The big picture
RedHill's acquisition of Rebyota and Clenpiq marks a strategic shift toward a larger, controlled commercial GI business. The move comes amid broader industry trends of consolidation and refocusing on core therapeutic areas. With $37.5M in combined sales, the assets provide immediate revenue streams and growth opportunities, particularly as the aging population increases demand for GI treatments. The deal also positions RedHill to explore further acquisitions, leveraging its improved financial footing.
What we're watching
- Commercial Execution
- Whether RedHill can effectively integrate and grow sales of Rebyota and Clenpiq, leveraging its existing commercial team.
- Market Expansion
- The pace at which RedHill can expand Rebyota's reach beyond the U.S., following its recent approval in Canada.
- Strategic Acquisitions
- How RedHill's strengthened liquidity position will influence its ability to pursue additional revenue-generating product acquisitions.
Related topics